Botulinum Neurotoxin (BoNT) as new treatment for functional (psychogenic) jerky movementdisorders.

Conditions: Botulinum neurotoxin (BoNT) has emerged as a useful therapy for several movement disorders associated with muscle overactivity such as dystonia and jerky movement disorders. At least 2–9% of patients seen in movement disorder clinics suffer from movement disorders with a psychogenic origin and a substantial part of them has jerks. These psychogenic jerky movement disorders cannot be accounted for by a known neurologic syndrome.

Registration Number: NL-OMON26050

Lead Sponsor: Academic Medical Center University of AmsterdamPO-box: 226601100 DD AmsterdamTel: 0031 (0)20 5669111

Brief Summary: /A

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 54

Inclusion Criteria

Patients with at least one invalidating consistent type of psychogenic jerk that is present for 1 year or longer.
Patients with one consistent type of invalidating tremor present for one year or longer .

Exclusion Criteria

1. Age < 18 years or > 80 years;

2. Psychogenic jerk of interest present for < 1 year;

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess whether treatment with BoNT leads to improvement of psychogenic jerks according to an independent movement disorder specialist assessed with the Clinical Global Impression - Improvement scale.

Secondary Outcome Measures

Name	Time	Method
The effect of BoNT on:<br /><br>1. The severity of jerks according to a movement disorder specialist;<br /><br>2. Improvement and severity of the jerk according to the patient;<br /><br>3. Nature and severity of overall dyskinesia;<br /><br>4. Jerk frequency;<br /><br>5. Whether patients consider treatment with BoNT effective;<br /><br>6. Disability;<br /><br>7. Quality of life;<br /><br>8. Co-existent psychiatric disorders;<br /><br>9. The occurrence of adverse reactions;<br /><br>10. Muscle weakness.